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The use of peripheral blood mononuclear cells (PBMC) for transcriptome analysis has already been proven valuable for assessing disease-
associated and drug-response-related gene signatures. While these proof-of-principle studies have been critically important, the instability of RNA
within PBMC prohibits their use in large-scale multicenter trials for which samples have to be transported for a prolonged time prior to RNA
isolation. Therefore, a prerequisite for transcriptome analysis of peripheral blood in clinical trials will be a standardized and valid method to
stabilize the RNA profile immediately after blood withdrawal. Moreover, to be able to perform such large-scale clinical studies routinely in several
hundred patients more cost-effective array technologies are required. To address these critical issues, we have combined a whole-blood RNA
stabilization technology with a method to reduce globin mRNA, followed by genome-wide transcriptome analysis using a newly introduced
BeadChip oligonucleotide technology. We demonstrate that the globin mRNA reduction method results in significantly improved data quality of
stabilized RNA samples with low intragroup variance and a detection rate of expressed genes similar to that in PBMC. More important, even small
differences in gene expression such as are observed between females and males were detected and sufficient to predict gender in whole-blood
samples. We therefore propose the combination of globin mRNA reduction after whole-blood RNA stabilization with a newly introduced cost-
effective BeadChip array as the preferred approach for large-scale multicenter trials, especially when establishing predictive markers for disease
and treatment outcome in peripheral blood.
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genome-wide technology to be considered for routine clinical
use [1,2]. In fact, numerous landmark studies, particularly in
cancer research, have highlighted the power of this technology
to improve molecular diagnostics [3–6], prediction of prog-
nosis at diagnosis [7–11], and even prediction of drug efficacy
[12–14]. These landmark studies led to the acceptance of the
technology and its significantly increasing use, especially in
clinical medicine. More recently, peripheral blood mononuclear
cells (PBMC) have been used to study transcriptome profiles in
systemic lupus erythematosus [15–17], acute myeloid leuke-0888-7543/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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1 These authors contributed equally to this work.mia [11], renal cell carcinoma (RCC), or drug response in RCC
[18].
Guidelines for reporting, annotation, and data analysis of
microarray data have been set (MIAME [19]), and recent
reports have focused on the impact of different microarray
platforms and lab-to-lab variability in reproducibility and
comparability of microarray results [20–22], suggesting the
use of highly standardized protocols from RNA amplification
to data analysis. While the latter findings are of great
importance, still too little attention has been paid to sample
procurement, storage, and preparation, particularly when using
peripheral blood or PBMC for transcriptome analysis. We and
others have demonstrated that sample handling and prolonged
transportation significantly influence gene expression profiles
[23,24]. Particularly concerning is the development of a6) 653 – 664
www.el
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after delayed sample handling [23], since such influences seem
to have a significant impact on expression signatures associated
with, e.g., malignant diseases (T. Zander, unpublished obser-
vation). For multicenter trials, it has been demonstrated that
significant effort will be necessary to achieve a high grade of
standardization leading to good quality gene expression data
when using PBMC [25]. To overcome these limitations, new
approaches have been developed to stabilize gene expression
profiles, especially in peripheral blood. One of the most
promising techniques for whole-blood sample handling in
clinical trials is the PAXgene Blood RNA System, which
allows standardized blood collection. While analysis of
individual genes by RT-PCR in PAXgene-stabilized blood
samples suggested stability of mRNA expression even after
prolonged sample storage [24], we have recently demonstrated
that blood samples prepared with the PAXgene system
demonstrate a significant increase in overall variability and
reduction in present call rates when applying Affymetrix
microarray technology, limiting its application for large-scale
expression profiling studies. It has been speculated that the
reduced sensitivity and also the variability might be due to the
predominant amount of globin mRNA transcripts in whole-
blood samples [23,26].
Because peripheral blood is most likely to become the
prime tissue for prediction of treatment and disease outcome
or diagnosis of systemic diseases, a method is critically
needed that addresses the current limitations of gene ex-
pression profiling of peripheral blood. For large-scale clinical
trials, a substantial cost reduction in currently available gene
expression technology will also be of great importance. We
have addressed these limitations by evaluating a method that
combines stabilization of expression profiles in whole-blood-
derived RNA samples with a globin mRNA reduction
approach. This method results in improved microarray results
such as increased present calls and reduced variance. More
important, we demonstrate for the first time that this method
increases the sensitivity toward overall small differences in
gene expression profiles between two groups, as assessed by
the establishment of more robust classifiers for gender
prediction than with PAXgene samples that were not
subjected to globin reduction. Furthermore, we demonstrate
that whole-blood-derived RNA samples prepared by this
method can be successfully applied to a newly introduced
and very cost effective bead-based oligonucleotide microarray
(Illumina BeadChip) platform, thus providing a reliable,
robust and cost-effective method allowing genome-wide gene
expression profiling of peripheral blood in large clinical
trials.
Results
Improvement of array performance of whole-blood samples by
globin mRNA reduction
To apply transcriptome analysis to large multicenter clinical
trials, RNA derived from peripheral blood needs to bestabilized directly after blood withdrawal to prevent ex vivo
transcriptional changes [23]. PAXgene (PAX) is a commer-
cially available system stabilizing RNA profiles in blood
samples. However, we previously observed a large intragroup
variance and low rates of genes detected as present (‘‘present
calls’’) in whole-blood samples prepared by PAX [23].
Therefore, the use of whole-blood samples in clinical trials
depends on the improvement of both present call rate and
variance. The high abundance of globin mRNA has been
suggested to account for these limitations [23,26]. We
therefore tested the impact of a methodology to reduce globin
mRNA from total RNA prepared with PAXgene prior to array
analysis (PAX-GRP) on present call rate and variance. Gene
expression profiles of PAX-stabilized blood samples either
with or without reduction of globin mRNA from 14 healthy
individuals including 7 females and 7 males were assessed on
the Affymetrix platform (U133A). As demonstrated in Fig.
1A, samples prepared with PAX-GRP showed a reduced
variance compared to PAX samples, suggesting that the globin
mRNA reduction is beneficial to the quality of the dataset.
Furthermore, present call rates for PAX-GRP samples signif-
icantly ( p < 0.001) increased from 40.98 T 3.27% for PAX
samples to 49.99 T 3.27% for PAX-GRP samples (Fig. 1B). In
comparison to a historical control of PBMC samples (56.7 T
2.8%), the present call rate of PAX-GRP samples was now
almost in the same range as the PBMC samples. Successful
removal of globin transcripts in PAX-GRP samples was also
demonstrated by agarose gel electrophoresis of the generated
cRNA products (Fig. 1C). The initial discrete cRNA bands
derived from highly abundant globin mRNA transcripts in
PAX samples changed to the typical cRNA smear pattern after
globin reduction. These findings are in concordance with a
significant ( p < 0.001) decrease in the signal intensities for the
a1 (37,38%; probe set 211699_x_at), a2 (39,93%; probe set
211745_x_at), and h hemoglobin transcripts (48,13%; probe
set 211696_x_at) (Fig. 1D).
A limitation of the PAX-GRP method could be a nonspe-
cific deletion of transcripts other than globin due to the RNase
H treatment. In this case signal intensities for such transcripts
should be higher in PAX samples compared to PAX-GRP
samples despite the overall reduction of present calls in PAX
samples. To assess this issue, we performed a comparison
analysis of the two experimental groups (PAX vs. PAX-GRP)
with fold change >2 and difference of mean >50 as filtering
criteria. In total we found 415 transcripts with higher mean
signal intensities in PAX samples (1.86% of all transcripts
assessed). To assess whether the differences in mean signal
intensities were statistically significant for each probe set and
all sample pairs (PAX vs. PAX-GRP), we performed two-
sample t tests ( p < 0.05) for each of the 415 transcripts, each
represented by 11 perfect-match probes on the U133A arrays,
in the 14 corresponding sample pairs, resulting in 5810 t tests.
Most surprising, in 90.7% (5267) of the t tests performed, no
significant differences between PAX and PAX-GRP were
revealed. For only 9 of the 415 transcripts all 14 comparisons
revealed statistically significant differences. These genes have
been listed in Supplemental Table 2. We hypothesized that the
Fig. 1. Comparison of present call rates and variance in PAX and PAX-GRP samples. Gene expression data were generated using the Affymetrix U133A array. (A)
The variance for all probe sets was calculated within each group (PAX, n = 14; PAX-GRP, n = 14), ordered by rank, and plotted against the decade logarithm of the
rank. (B) The present calls were assessed with dCHIP1.3 software. The boundary of the box closest to 0 indicates the 25th percentile, the line within the box marks
the median, and the boundary of the box farthest from 0 indicates the 75th percentile. Whiskers above and below the box indicate the 90th and 10th percentiles.
Outliers are plotted as dots. *Significant vs. PAX, p < 0.001. (C) Original gel electrophoresis picture of cRNA derived from whole-blood samples prepared with
PAXgene (PAX; lanes 1a–4a) or cRNA generated from the same RNA samples after globin reduction (PAX-GRP; lanes 1b–4b). M, molecular weight marker. The
lanes between the cRNA samples are the respective fragmented cRNAs. (D) Signal intensities for hemoglobin without (PAX) or with removal of hemoglobin
transcripts (PAX-GRP). The boundary of the box closest to 0 indicates the 25th percentile, the line within the box marks the median, and the boundary of the box
farthest from 0 indicates the 75th percentile. Whiskers above and below the box indicate the 90th and 10th percentiles. Outliers are plotted as dots. *Significant vs.
PAX, p < 0.001.
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might be due mainly to an increased frequency of outliers in
the PAX samples. This can be assessed by determining the
variability of the signal intensities for the perfect-match probes.
As a measure of variability we calculated the relative standard
deviations (SD/mean) of the 11 perfect-match probes for the
415 transcripts in all 28 arrays and used these to build the ratios
between PAX and PAX-GRP samples ((SD/mean [PAX])/(SD/
mean [PAX-GRP])). We found that 98% of these ratios were
>1, indicating higher variance of signal intensity in PAXsamples compared to PAX-GRP samples due to outliers in the
perfect-match probes. Therefore, most differences between
PAX and PAX-GRP samples are not due to nonspecific
decrease in signals by the GRP method, but due to the higher
variability of signal intensity in PAX samples.
In summary, our data strongly suggest that qualitative
limitations in present call rates and variability of PAXgene
samples can be overcome by using PAXgene-based RNA
stabilization combined with reduction of globin mRNA
transcripts (PAX-GRP).
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samples
A typical approach when using transcriptome data to
determine disease or treatment outcome would be to build
classifiers to predict responders or nonresponders, patients with
respectively good or bad prognosis [7–10]. Several different
methods such as supervised learning models [3] or prediction
analysis of microarrays (PAM) [27] have been previously
applied to identify such predictors. For two reasons, we
initially chose to establish a class predictor for gender in a
dataset derived from PBMC samples. First, in previous studies
only PBMC and not whole-blood-derived RNA was used to
assess class predictors in patients with renal cell carcinoma,
lupus erythematosus, or juvenile arthritis. Second, we wanted
to use two distinct groups with preferably very small gene
expression differences to be able to determine whether more
clinically applicable methods of RNA preparation are also
usable to detect these minor differences of gene expression in
peripheral blood. Small differences between females and malesFig. 2. Unsupervised analyses of gender differences in PBMC. (A) Genes differentia
fold change >2, difference of mean >50, and p < 0.05. Analysis was performed in dC
samples. Hierarchical clustering of samples was performed with dCHIP1.3 softwar
Samples were clustered with genes selected by large variation across samples (0.5 <
Principal components analysis with 21 PBMC samples. Principal components analy
calculated and plotted.in peripheral blood were recently reported by Whitney et al.
[28].
In our study using PBMC samples for class comparison
analysis we also revealed very small gender-associated
differences (Fig. 2). Even when applying filter criteria of low
stringency (fold change >2, difference of mean >50; p < 0.05),
only eight transcripts were found to be differentially expressed
between the two groups (Fig. 2A). Six of the eight genes are
located on the Y chromosome and two genes are located on the
X chromosome. These differences are considerably smaller
than described, for example, for healthy controls and trauma
patients [25]. Reanalyzing this previously reported dataset with
the above described filter criteria revealed 308 differentially
expressed genes (data not shown). The rather small differences
between females and males in our dataset were also confirmed
by applying unsupervised methods such as hierarchical
clustering. Hierarchical clustering performed with genes
selected by large variation across samples (0.5 < standard
deviation/mean < 10) did not result in separation of female and
male subjects (Fig. 2B), indicating that differences in the genelly expressed in PBMC samples between females and males. Filter criteria were
HIP1.3 on data normalized also with dCHIP. (B) Cluster analysis of 21 PBMC
e using precalculated distances (1  correlation) and centroid linkage method.
standard deviation/mean < 10). Pink indicates females, blue indicates males. (C)
sis was performed using R software. Scores for each case and component were
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principal components analysis (PCA) we demonstrated that
variation within healthy individuals is not assigned to clearly
different subgroups. In summary the first three principal
components accounted for 57% of the overall variation within
the group of PBMC samples but no clear separation on gender
basis was detected (Fig. 2C).
Next we tested whether these small differences are sufficient
to build class predictors for gender. We used a dataset of
PBMC samples derived from 6 females and 6 males and
applied a supervised learning model using leave-one-out cross-
validation [3]. For this approach 5 to 60 features (genes used to
build a predictor) were used to predict the class assignment. As
shown in Fig. 3A, despite the small sample size of the dataset,
correct class assignment of all 12 samples was reached for all
predictors, although prediction confidence was low for some
individuals. As expected for two groups with small differences
in gene expression and a small sample size, mean values of
prediction confidence were high with predictors of small
feature sizes (5–10 features), but steadily decreased with
increasing features size. Including PBMC samples from an
additional 9 males in the analysis did not change the class
assignment. However, the larger sample size increased the
mean prediction confidence for predictors of larger feature size.
Furthermore, the previously poor performing samples demon-
strated also an increased prediction confidence, suggesting that
a larger dataset can lead to an even more robust classifier (Fig.
3B). In contrast to class prediction of gender, classifiers for
trauma patients were very robust even using large predictorFig. 3. Gender prediction in PBMC samples using leave-one-out cross-validation. (A
from 12 PBMC samples (6 females and 6 males) generated using Affymetrix U133A
predicted samples are denoted by open circles. Horizontal lines denote the mean pred
of 12 PBMC samples, 21 PBMC samples (6 females and 15 males) were used for the
in the R package MCRestimate. The misclassification rate was estimated by runnin
PAM classification using the 21 sample set.feature sizes (data not shown), further demonstrating that the
chosen model of gender prediction is most suited to interro-
gating novel approaches such as PAX-GRP for quality, since
very small differences in gene expression between two groups
can be assessed.
To corroborate the data derived from leave-one-out cross-
validation we used a second approach for class prediction of
gender—the estimation of misclassification errors by cross-
validation (MCR estimation)—which combines nested cross-
validation together with the PAM algorithm [27]. Starting with
the comparison of 6 females and 6 males this approach also
resulted in a correct class prediction for each individual (Fig.
3C) and this was also true when increasing the number of
individuals in the male sample group from 6 to 15 (Fig. 3D).
Taken together, despite the small number of significantly
changed genes, gender can already be predicted very accurately
in a rather small set of PBMC samples.
Globin reduction (PAX-GRP) increases accuracy and
confidence of prediction in datasets from PAX samples
Since we demonstrated that class predictors could be
established in a dataset derived from PBMC samples, we next
evaluated whether similarly small differences between genders
can be detected and whether class predictors can be generated
in data derived from the 14 PAX and PAX-GRP samples, as
described above. Calculating differences in gene expression by
class comparison analysis (fold change >2, difference of mean
>50; p < 0.05) revealed only four transcripts to be differentially) The scatter plot shows the gender prediction results within a dataset derived
arrays. Accurately predicted samples are denoted by closed circles, incorrectly
iction confidence. (B) An analysis similar to that shown in A. However, instead
analysis. (C) MCR estimation based on PAM classification [27] as implemented
g three reiterations of 10-fold cross-validation. (D) MCR estimation based on
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PAX-GRP samples (Fig. 4B). Three of the gender-specific
transcripts identified in PBMC samples were also identified in
PAX samples (Fig. 4A). The transcript of the granulysin gene
(GNLY) was the only one passing our filtering criteria in PAX
samples but not in PBMC samples. As we had already
previously observed, the gene expression values in PAX
samples assessed on the Affymetrix platform were generally
lower than for PBMC samples (compare Figs. 2A and 4A),
which might also be one of the reasons even fewer genes
passed our filtering criteria in PAX samples.
Class comparison analysis of PAX-GRP samples using the
same filtering criteria revealed nine transcripts to be differen-
tially expressed between females and males of which fourFig. 4. Class comparison analysis and gender prediction in PAX and PAX-GRP samp
males. Analysis was performed using the same criteria described for PBMC samples
similar to that shown in A. However, instead of 14 PAX samples, 14 PAX-GRP sam
the gender prediction results within a dataset derived from 14 PAX samples (7 ma
predicted samples are denoted by closed circles, incorrectly predicted samples are d
(D) MCR estimation of PAX samples based on PAM classification. The misclassifica
(E) An analysis similar to that shown in C. However, instead of 14 PAX samples, 1
estimation based on PAM classification using the PAX-GRP sample set.transcripts were also identified in PBMC samples (Fig. 4B).
These transcripts were located either on the X or the Y
chromosome, while the remaining five transcripts detected in
PAX-GRP samples were coded on chromosomes 2, 6, and 11
(Fig. 4B).
Next we applied the same methods described for PBMC
samples to generate class predictors for gender in PAX
samples. In contrast to PBMC samples we were unable to
establish a class predictor without misclassification of one
sample when applying the supervised learning model (Fig. 4C).
Misclassification was independent of feature size; even at very
low feature size misclassification was observed. Moreover, the
prediction confidence was greatly reduced compared to PBMC.
When applying MCR estimation algorithms we corroboratedles. (A) Genes differentially expressed in PAX samples between 7 females and 7
(FC >2, difference of mean >50, and p < 0.05) using dCHIP1.3. (B) An analysis
ples (7 females and 7 males) were used for analysis. (C) The scatter plot shows
les and 7 females) generated using the Affymetrix U133A arrays. Accurately
enoted by open circles. Horizontal lines denote the mean prediction confidence.
tion rate was estimated by running three reiterations of 10-fold cross-validation.
4 PAX-GRP samples (7 females and 7 males) were used for analysis. (F) MCR
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(Fig. 4D). These findings indicate that the overall quality of
expression data is decreased in PAX samples and might
therefore not be applicable to detecting slight differences in
gene expression or to establish valid class predictors in samples
with small differences in gene expression.
Based on the increased quality of the data generated from
PAX-GRP samples, we postulated that class prediction in
these samples compared to PAX samples might also be
improved. Similar to PBMC and PAX samples we first used
the supervised learning model [3]. Leave-one-out cross-
validation with predictors comprising 5 to 60 features was
established to predict gender in PAX-GRP samples. In
contrast to PAX samples and similar to PBMC samples,
PAX-GRP samples were always assigned correctly with
sufficient mean prediction confidence (Fig. 4E). Furthermore,
MCR estimation also resulted in correct class prediction for
each individual (Fig. 4F). Taken together, gene expression
analysis of whole-blood samples prepared by the PAX-GRP
method can be successfully used to build class predictors to
differentiate two classes of even small differences in overall
gene expression.
Comparability of PAX-GRP samples assessed on Affymetrix
and Illumina arrays
In multicenter trials, large numbers of samples have to be
analyzed. Therefore, inexpensive technology is a prerequisite
for general clinical use. The newly launched Illumina gene
expression analysis platform [29] allows higher throughput
with significantly lower costs (¨50% less) in comparison to
other currently used microarray systems. A further critical point
is the amount of total RNA required for microarray analysis in
a clinical setting. For example, in comparison to the Affymetrix
technology for which a minimum of 5 Ag of total RNA is
needed for target cRNA preparation with a single round of in
vitro transcription, only 50–500 ng total RNA is required for
the Illumina platform. Since the overall performance of
microarray technology is also dependent on the quality of the
sample preparation, we tested whether the Illumina technology
could be combined with RNA samples prepared by the
PAXgene method followed by globin mRNA reduction. For
comparison between the results obtained on the Affymetrix
platform and the Illumina platform, we assessed gene
expression on Illumina Sentrix humanref-8 BeadChip arrays
targeting 24,136 transcripts in the same PAX-GRP samples that
were used for the analysis on the Affymetrix platform (U133A
array). Next, platforms were cross-annotated using gene
symbols for the respective genes. The Illumina Sentrix
humanref-8 BeadChip harbors 24,136 probes representative
of 18,957 annotated genes in comparison to the U133A
Affymetrix array interrogating 12,846 well-annotated genes
using 22,215 probes. Commonly represented on both platforms
were 11,398 genes as defined by an existing gene symbol.
Overall, the large majority of well-annotated genes on the
U133A array is also represented on the newly introduced
Illumina Sentrix humanref-8 BeadChip array.Applying stringent criteria to determine present calls on the
Illumina arrays, an average of 46.6 T 3.7% of the genes
demonstrated a significant hybridization signal compared to
background signal within the 14 PAX-GRP samples. This is
similar to the average present call rate observed on the
Affymetrix platform. For comparison of the two platforms, a
gene was defined as ‘‘expressed’’ when at least one probe
(Illumina) or one probe set (Affymetrix) representing a
corresponding gene was called present in all 14 PAX-GRP
samples. Accordingly, within the shared gene space 5930 genes
were expressed on the Sentrix humanref-8 BeadChip arrays,
while only 4438 genes were expressed on Affymetrix U133A
arrays (Fig. 5A). A majority of genes called expressed in PAX-
GRP samples were detected on both platforms (3979 genes).
To investigate whether one or both techniques introduce
variability due to technical reasons, we compared the coeffi-
cient of variation of the data assessed by Affymetrix arrays
versus those assessed by Illumina arrays. When calculating the
coefficient of variation of all well-annotated genes represented
on both platforms there was a slightly lower coefficient of
variation in samples analyzed on the Illumina platform (Fig.
5B). This decreased variability may be due to the higher
stringency of the 50-mer-based Illumina BeadChip array
compared to the 25-mer-based Affymetrix array.
To visualize the impact of the array platform on the
expression profile we performed dimension reduction using
PCA. To compare both sample groups directly we set the
maximum score for each sample to 1. When performing PCA
with the 14 PAX-GRP samples analyzed by Illumina and
Affymetrix microarrays no distinction between the two plat-
forms was found, indicating that gene expression data generated
on both platforms exhibit good comparability (Fig. 5C).
Correct gender prediction in PAX-GRP samples analyzed on
high-density BeadChip arrays
For comparison analysis and establishment of class pre-
dictors we primarily used the complete gene set (18,957 genes)
interrogated by the Sentrix humanref-8 BeadChip array. Class
comparison analysis using the same filtering criteria as
described above revealed a total of 10 transcripts to be
differentially expressed (Fig. 6A). Five of these transcripts
(RPS4Y1, DDX3Y, SMCY, EIF1AY, CYorf15B) were also
detected as differentially expressed between females and males
in PBMC samples (see Fig. 2A). Probes to detect transcripts
derived from the genes PHACSand RPS4Y2 are not represented
on the Affymetrix U133A array, while two not yet annotated
sequences (AA628440, AV699347) are not represented on the
Illumina Sentrix humanref-8 bead array. Whereas granulysin
(GNLY) was detected to be differentially expressed only in
PAX-GRP samples (irrespective of the platform used), USP9Y
(ubiquitin-specific protease 9, Y chromosome) was detected to
be differentially expressed only in PBMC samples.
Next we analyzed gender predictability in this dataset using
the same algorithms as for the Affymetrix dataset. When
applying leave-one-out cross-validation, predictors with up to
20 features classified all samples correctly (Fig. 6B). Only with
Fig. 5. Platform comparison for PAX-GRP samples using Affymetrix or
Illumina arrays. (A) Venn diagram illustrating the gene space (11,398 genes)
shared by the Affymetrix U133A array and the Illumina Sentrix humanref-
8 bead array. Shown are the genes expressed on either both or only one
platform within the common gene space. (B) All well-annotated genes
represented on both platforms were taken to calculate the coefficient of
variation. Standard deviation of the intensity of each probe (Illumina arrays) or
probe set (Affymetrix arrays) was calculated and divided by the mean intensity.
Resulting coefficients of variation were ranked and plotted. A probe set may be
plotted twice as matching with two different bead probe sequences. (C)
Principal components analysis with 14 PAX-GRP samples analyzed on the
Illumina and the Affymetrix platform. Analysis was performed using R
software. Scores for each case were calculated and the first three components
were plotted. Different numbers of probes were used for PCA on the Illumina
and Affymetrix platform. Therefore, scores were normalized to a maximum of
1 to compare both groups.
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GRP samples analyzed using Affymetrix U133A arrays
showed no misclassification at higher feature sizes, these
differences were not significant as assessed with Fisher’s exacttest (significance level for comparison Illumina vs. Affymetrix
p = 0.2). In contrast, when MCR estimation [27] was used, a
perfect gender prediction was performed in all cases analyzed
on the Illumina platform (Fig. 6C).
Performing class prediction within the shared gene space of
11,398 genes, misclassification was observed in PAX-GRP
samples assessed on Affymetrix arrays only when using
predictors with high feature size. In contrast, no misclassifica-
tion was observed with predictors of up to 60 features when
assessing the same PAX-GRP samples on Illumina arrays
within the shared gene space (Supplemental Fig. 1). Again,
these differences were not statistically significant.
Taken together, the overall performance of PAX-GRP
samples analyzed on the Illumina platform was comparable
to that of the Affymetrix platform. The Illumina system shows
adequate sensitivity to discriminate between females and
males, therefore allowing the assessment of very small
biological differences between two groups. These findings
together with the merits of low cost per sample and very low
requirements of total RNA for microarray analysis reveal the
Illumina platform as an attractive tool to enable cost-effective
blood-based genomics studies.
Discussion
Transcriptome analysis of peripheral blood is a very
promising approach to determining disease and treatment
outcome [11,15–18,23,28]. Unfortunately, current approaches
based on the assessment of gene signatures in PBMC are
applicable to multicenter clinical trials or even routine medical
use only when PBMC are isolated as soon as possible after
blood withdrawal at the clinical site, which demands a
substantial organizational effort [25]. Furthermore, we have
demonstrated recently that samples that cannot be processed
immediately for gene expression profiling experiments yield
significantly reduced data quality [23]. To circumvent such
pitfalls, stabilization techniques for gene expression profiles in
whole-blood samples have been introduced [24]. However,
these techniques are associated with other technical problems
of genome-wide transcriptome analysis such as significantly
reduced overall present call rates, inferior data quality as
assessed by increased intragroup variance [23], or decreased
concordance in gene expression compared to expression
profiles derived from PBMC samples [25]. Another important
hurdle prohibiting large-scale clinical trials are the still
significant costs of genome-wide transcriptome analyses [30].
Therefore, a method that could be used in large-scale
multicenter trials or even for routine use would require the
following: (1) a highly standardized and simple method for
sample collection and processing with minimal hands-on time
and without introducing ex vivo changes, (2) a method for
genome-wide transcriptome analysis that can discriminate very
small expression differences between two classes, (3) a method
for which only small amounts of RNA are needed to minimize
the volume of blood required for analysis, and (4) a cost-
effective transcriptome technology allowing analysis of higher
sample numbers at reasonable cost. Here we have addressed
Fig. 6. Gender prediction in PAX-GRP samples using Sentrix humanref-8 bead arrays. (A) Genes differentially expressed in PAX-GRP samples between 7 females
and 7 males as assessed using the Illumina Sentrix humanref-8 bead arrays. Data were primarily assessed using Illumina software. Date were imported into dCHIP1.3
and normalized and class comparison analysis was performed (FC >2, difference of mean >50, and p < 0.05). Genes significantly different according to the filtering
criteria are listed. (B) The scatter plot shows the gender prediction results within a dataset derived from 14 PAX-GRP samples (7 females and 7 males) generated
using the Illumina platform. Accurately predicted samples are denoted by closed circles, incorrectly predicted samples are denoted by open circles. Horizontal lines
denote the mean prediction confidence. (C) MCR estimation based on PAM classification. The misclassification rate was estimated by running three reiterations of
10-fold cross-validation.
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stabilization using PAXgene, (2) globin mRNA reduction, and
(3) the newly introduced cost-effective Illumina Sentrix
BeadChip array for genome-wide transcriptome analysis of
small whole-blood-derived RNA samples (as small as 100 ng/
sample). We demonstrate that this methodology leads to high-
quality data with low intragroup variance and a present call rate
comparable to currently used methodology assessing PBMC.
More important, this method can be successfully applied to
build class predictors even for classes of very small differences
in gene expression such as gender–associated expression
differences in blood cells [28]. We therefore propose this
method to be applied to peripheral blood in large-scalemulticenter clinical trials assessing disease or treatment
outcome.
We and others have previously observed that RNA derived
from whole-blood samples exhibits a reduced data quality after
RNA stabilization leading to high variability and reduced
sensitivity toward leukocyte-derived transcripts [23,26]. The
abundant expression of RNAs derived from globin transcripts
was the most likely explanation for poor data quality of whole-
blood samples prepared with PAXgene. In fact, when reducing
globin mRNA transcripts prior in vitro transcription (PAX-
GRP samples) both intragroup variance and present call rate
were greatly improved. While we used RNase H digestion of
globin oligonucleotides/globin mRNA hybrids in our study an
S. Debey et al. / Genomics 87 (2006) 653–664662alternative method to remove globin transcripts has been
introduced recently. Current experiments are addressing
whether this method (1) allows removal of globin transcripts
from smaller amounts of initial total RNA input and (2) results
in data of similar quality with low intragroup variance,
sufficient present call rate, and higher sensitivity for class
predictor development (S. Debey, unpublished results).
The still rather large amount of RNA required for genome-
wide transcriptome analysis using currently commercially
available microarray technologies and their still high expenses
have so far prohibited applying these technologies to large-
scale clinical trials for the development of predictive
signatures for disease or treatment outcome. The newly
introduced Illumina BeadChip array platform is significantly
more cost-effective (¨50% less) than other currently available
technologies. Moreover, the small amount of 100 ng per
sample of RNA needed to perform a genome-wide expression
analysis on this platform is of great benefit for clinical trials
since it allows one to reduce significantly the blood sample
size for each patient at any given time point during a clinical
study. As shown here for gender differences, stabilized RNA
from peripheral blood combined with globin mRNA reduction
and use of the Illumina BeadChip technology is most
appropriate to detect small differences between two defined
groups.
The importance of standardization of blood sample handling
and processing procedures as provided here can be further
illustrated by reassessing previously published and publicly
available data derived from PBMC. For this purpose we have
established a predictor for delayed sample handling of PBMC
samples (T. Zander, unpublished results). Many genes associ-
ated with this predictor are related to hypoxia [23]. When
applying this predictor to previously published datasets, a large
number of these samples was classified similar to samples
assessed after prolonged handling time (T. Zander, unpublished
results). Under these circumstances signatures related to real
pathophysiology and technically induced changes cannot be
distinguished any more, making it difficult to interpret such
datasets correctly.
We conclude that the prerequisites—reproducibility, feasi-
bility, and affordability—for using gene expression profiling of
blood in large clinical multicenter trials can be met by
combining PAXgene technology to stabilize expression profiles
during sample processing and transportation, reducing globin
mRNA to increase quality of expression data, using only a
single round of in vitro transcription and employing affordable
microarray technology, which still complies with high industry
standards. Having these techniques in place will now allow the
widespread use of gene expression profiling in validation
studies and further clinical applications.
Material and methods
Sample collection and RNA preparation
Blood samples from apparently healthy female or male blood donors were
collected in PAXgene collection tubes (Qiagen, Hilden, Germany) after
written informed consent had been obtained and following approval by theinstitutional review board. Age, body mass index, and time of blood draw
showed no significant differences between females and males. Alternatively,
PBMC were prepared following previously published methods [23]. RNA was
prepared with the PAXgene Blood RNA Kit (Qiagen) according to the
manufacturer’s instruction including an optional DNase digestion step. In the
case of PBMC, RNA was prepared by the Trizol method as previously
described [23].
Globin reduction protocol
Globin reduction was performed according to an Affymetrix technical note
[31]. To reduce globin mRNA 8 Ag of total RNA prepared with the PAXgene
Blood RNA Kit was incubated in 10 mM Tris–HCl, pH 7.6, 20 mM KCl (total
volume 10 Al), with the globin-specific oligos a1, 5V-TGCAGGAAGGGGAG-
GAGGGGCTG-3V (1.5 AM); a2, 5V-TGCAAGGAGGGGAGGAGGGCCCG-3V
(1.5 AM); h, 5V-CCCCAGTTTAGTAGTTGGACTTAGGG-3V (4 AM) for 5 min
at 70-C and then cooled to 4-C. Globin mRNA–DNA hybrids were removed
by adding 10 Al of RNase H digestion mix (2 units RNase H, 20 mM Tris–
HCl, pH 7.6, 2 mM DTT, 4 mM MgCl2) and incubating for 10 min at 37-C.
Samples were cooled to 4-C and reactions were stopped by adding 1 Al of 0.5
M EDTA. RNase H-treated RNA samples were then purified with IVT cRNA
Cleanup spin columns from the Affymetrix GeneChip Sample Cleanup Module
according to the manufacturer’s protocol and globin-depleted RNA was eluted
with 14 Al H2O. The integrity of the RNase H-treated RNA samples was
assessed by Agilent 2100 bioanalyzer analysis prior to in vitro transcription
(IVT) and revealed RNA of normal quality.
Microarray procedure using Affymetrix U133A arrays
Three to five micrograms of globin-depleted total RNA was used to
generate double-stranded cDNA with a T7(dT)24-oligonucleotide primer
performed with a One Cycle cDNA Synthesis Kit (Affymetrix, Santa Clara,
CA, USA). After purification with the Sample Cleanup Module (Affymetrix),
cDNA served as a template to prepare biotinylated cRNA via IVT, using the
IVT Labeling Kit (Affymetrix). The labeled cRNA transcripts were purified
using the Sample Cleanup Module and assessed for quantity and quality by UV
spectroscopy and electrophoresis. Fragmentation of cRNA transcripts, hybrid-
ization, and scanning of the high-density oligonucleotide microarrays (HG-
U133A arrays; Affymetrix) were performed according to the manufacturer’s
GeneChip Expression Analysis Technical Manual (Affymetrix).
Microarray procedure using Illumina Sentrix humanref-8 arrays
One hundred nanograms of globin-depleted total RNA was used for first-
and second-strand cDNA synthesis performed with a MessageAmp Kit
(Ambion, Cambridgeshire, UK) using quarter volumes. Purification of cDNA
was performed with a QiaQuick PCR Purification Plate on a QIAvac 96
vacuum manifold (Qiagen, Chatsworth, CA, USA). Biotin-labeling of cRNA
was performed with biotin-16–UTP (Perkin–Elmer) and the MessageAmp Kit,
and cRNA was purified using an RNeasy Plate (Qiagen) on a QIAvac 96
vacuum manifold. Hybridization and scanning of Sentrix humanref-8 expres-
sion bead arrays were performed according to the manufacturer’s instructions
(Illumina, San Diego, CA, USA).
Data extraction and statistics
For Affymetrix data collection and assessment, we used Affymetrix
Microarray Analysis Suite version 5.0 (MAS5.0) and dCHIP 1.3. According
to standard microarray analysis methods, for data analysis using MAS5.0 the
fluorescence intensity of each array was scaled to an overall intensity of 100 to
enable comparison of all hybridization data. In dCHIP Affymetrix CEL files
were imported and normalized to the median intensity using the Perfect Match
model [32]. Data extraction for Illumina was performed using the AnEx software
and dCHIP 1.3. In dCHIP 1.3 Illumina raw expression values were imported as
external data and normalized to the median intensity. Differentially expressed
genes were assessed using dCHIP1.3. For variance analysis and Fisher’s exact
test, the R software was used. For comparison we also analyzed a previously
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(http://www.ncbi.nlm.nih.gov/geo/; accession number GSE2328).
Comparison between the Affymetrix U133A array and the Illumina
Sentrix humanref-8 bead arrays
For comparison of the two platforms we cross-annotated the Affymetrix
probe set IDs as well as the Illumina oligonucleotide IDs to gene symbols. Data
were retrieved from the most current annotation file from the Affymetrix
NetAffx Web site (http://www.affymetrix.com/support/technical/byproduct.
affx?product = hgu133) and the annotation file supplied by Illumina. Gene
symbols and alternative variants of the gene symbol (called ‘‘synonyms’’ within
the Illumina annotation file) were taken for cross-annotation. By using gene
symbols for cross-annotation it is possible that differentially spliced transcripts
that are interrogated differentially on both platforms are merged within one
gene symbol. Cross-annotation was performed using a relational MS Access
database that linked Affymetrix probe sets and Illumina oligonucleotide IDs
with gene symbols.
After cross-annotation the variance for each bead probe and the respective
probe set was calculated for the Illumina or Affymetrix samples and divided by
the mean expression value for the respective bead probe or probe set. The
obtained coefficient of variation was sorted and ranked.
Principal components were calculated using R software and scores for each
case were plotted. As size of the scores depends on the number of variables
used for PCA, we normalized scores for each group (Illumina or Affymetrix) to
a maximum of 1.
Calculation of present calls for Illumina data
Image analysis and data extraction were performed using Illumina AnEx
software. Briefly, each sequence type is represented by an average of 30 beads
on the array. Bead signals are computed with weighted averages of pixel
intensities, and local background is subtracted [33]. Sequence-type signal is
calculated by averaging corresponding bead signals with outliers removed
(using median absolute deviation). Detection p values were computed using a
model based on signals of negative controls as described by Fan et al. [34]. To
correct for multiple testing a Bonferroni correction on a p value of 0.05
was applied. Consequently those signals differing from the background with
a p value of 0.05/24,115 were called present.
Prediction of gender
For class predictions using several different algorithms expression values
from the respective datasets were exported from dCHIP1.3. First GeneClus-
ter2 software [3] was used and the data were preprocessed as follows:
Signal intensities below 20 and above 16,000 (Affymetrix) or below 5 and
above 5000 (Illumina) were set to the respective minimum and maximum
values, and data were normalized to mean = 0 and variance = 1. In the
supervised learning approach predictors were generated and tested by the
leave-one-out cross-validation model using the weighted voting algorithm.
Furthermore, nested cross-validation based on PAM classification [27] was
used to predict the class membership [35] as implemented in the R package
MCRestimate. Here the misclassification rate was estimated by running three
reiterations of 10-fold cross-validation. Generation of class predictors for
gender was also performed in the gene space shared between Affymetrix
and Illumina arrays.
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